Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADA-1: Palbociclib + HT Driven by ctDNA ESR1 Mutation Monitoring in ER+/HER2- Metastatic Breast Cancer
NCT03079011Phase 3Completed
- Sponsor
- Unicancer
- Start
- Mar 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of palbociclib in breast cancer, sponsored by Unicancer. Started Mar 2017; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03079011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079011.